Published in N Engl J Med on October 18, 2012
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol (2014) 2.82
Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest (2014) 2.39
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology (2013) 1.58
Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol (2017) 1.42
mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile. PLoS One (2016) 1.41
Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol (2016) 1.39
A functional genomics predictive network model identifies regulators of inflammatory bowel disease. Nat Genet (2017) 1.38
Interleukin-12 and Interleukin-23 Blockade in Leukocyte Adhesion Deficiency Type 1. N Engl J Med (2017) 1.37
The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol (2015) 1.34
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med (2015) 1.32
Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol (2015) 1.29
How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med (2013) 1.26
New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25
Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology (2013) 1.24
Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol (2014) 1.17
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med (2015) 1.15
Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Invest (2015) 1.14
Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol (2014) 1.09
Role of interleukin 23 signaling in Clostridium difficile colitis. J Infect Dis (2013) 1.05
Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm (2014) 1.04
Inflammatory bowel disease and celiac disease: overlaps and differences. World J Gastroenterol (2014) 1.03
The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol (2015) 1.03
Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol (2014) 1.03
Treatment of IBD: where we are and where we are going. Am J Gastroenterol (2014) 1.02
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol (2015) 0.94
Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol (2015) 0.94
Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. Am J Respir Crit Care Med (2015) 0.92
Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet (2013) 0.91
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol (2015) 0.91
The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol (2015) 0.90
New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne) (2014) 0.89
CXCL5 drives neutrophil recruitment in TH17-mediated GN. J Am Soc Nephrol (2014) 0.89
Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm (2015) 0.89
Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J (2015) 0.88
Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res (2014) 0.88
New evidence on the management of spondyloarthritis. Nat Rev Rheumatol (2016) 0.87
Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells. Mucosal Immunol (2014) 0.87
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis (2015) 0.86
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. Patient Prefer Adherence (2013) 0.86
Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci (2014) 0.85
Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo. J Biol Chem (2014) 0.85
Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitis. Immunotherapy (2013) 0.85
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet (2017) 0.85
Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol (2013) 0.84
Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res (2015) 0.83
Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol (2016) 0.83
The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Arch Immunol Ther Exp (Warsz) (2015) 0.82
Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma. Clin Dev Immunol (2013) 0.82
Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am (2014) 0.82
Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity? J Pathol (2014) 0.82
Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease. Gastroenterology (2016) 0.81
When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease. Clin Exp Gastroenterol (2014) 0.81
Pathogenesis of Crohn's disease. F1000Prime Rep (2015) 0.81
Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol (2014) 0.81
IL12Rβ1: the cytokine receptor that we used to know. Cytokine (2014) 0.81
CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol (2015) 0.80
Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort. PLoS One (2015) 0.80
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
Strategies to direct the enrichment, expansion, and recruitment of regulatory cells for the treatment of disease. Ann Biomed Eng (2014) 0.80
Ustekinumab for Successful Treatment of Refractory Esophageal Crohn's Disease. ACG Case Rep J (2016) 0.80
Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol (2014) 0.80
Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology (2016) 0.80
Harnessing regulatory T cells for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.79
Regulation of T-lymphocyte motility, adhesion and de-adhesion by a cell surface mechanism directed by low density lipoprotein receptor-related protein 1 and endogenous thrombospondin-1. Immunology (2014) 0.79
Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol (2014) 0.79
Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair. Gastroenterology (2016) 0.79
Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis (2015) 0.78
Down-regulation of human enteric antimicrobial peptides by NOD2 during differentiation of the paneth cell lineage. Sci Rep (2015) 0.78
Takayasu's Arteritis and Crohn's Disease in a Young Hispanic Female. Case Rep Rheumatol (2014) 0.78
Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain. J Biol Chem (2015) 0.78
Current stage in inflammatory bowel disease: What is next? World J Gastroenterol (2015) 0.78
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res (2014) 0.78
Revisited HLA and non-HLA genetics of Takayasu arteritis-where are we? J Hum Genet (2015) 0.78
Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases. AAPS J (2015) 0.77
IBD in 2012: Pathogenesis and management of IBD--thinking outside the box. Nat Rev Gastroenterol Hepatol (2013) 0.77
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice. Biol Blood Marrow Transplant (2015) 0.77
Protein microarrays identify disease-specific anti-cytokine autoantibody profiles in the landscape of immunodeficiency. J Allergy Clin Immunol (2015) 0.77
IL-17F Promotes Tissue Injury in Autoimmune Kidney Diseases. J Am Soc Nephrol (2016) 0.77
Induction of Colonic M Cells during Intestinal Inflammation. Am J Pathol (2016) 0.77
Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol (2015) 0.77
Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology. Clin Rheumatol (2015) 0.77
Molecular Signaling and Dysfunction of the Human Reactive Enteric Glial Cell Phenotype: Implications for GI Infection, IBD, POI, Neurological, Motility, and GI Disorders. Inflamm Bowel Dis (2016) 0.76
CPAG: software for leveraging pleiotropy in GWAS to reveal similarity between human traits links plasma fatty acids and intestinal inflammation. Genome Biol (2015) 0.76
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators Inflamm (2015) 0.76
Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice. Eur J Immunol (2016) 0.76
Ustekinumab in Crohn's disease: evidence to date and place in therapy. Ther Adv Chronic Dis (2016) 0.76
Ustekinumab for the treatment of Crohn's disease: can it find its niche? Therap Adv Gastroenterol (2016) 0.76
IBD: Ustekinumab shows promise in the treatment of refractory Crohn's disease. Nat Rev Gastroenterol Hepatol (2012) 0.76
Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep (2016) 0.76
Prostaglandin E2-EP4 signaling persistently amplifies CD40-mediated induction of IL-23 p19 expression through canonical and non-canonical NF-κB pathways. Cell Mol Immunol (2015) 0.76
Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease. Curr Allergy Asthma Rep (2016) 0.76
Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World J Gastrointest Pathophysiol (2014) 0.76
Neuroinflammation - using big data to inform clinical practice. Nat Rev Neurol (2016) 0.75
Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol (2014) 0.75
New and emerging therapies for inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2012) 0.75
IL-17 Signaling: The Yin and the Yang. Trends Immunol (2017) 0.75
Ustekinumab for moderate-to-severe Crohn's disease. Gastroenterology (2013) 0.75
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet (2008) 15.51
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet (2004) 5.83
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (2012) 5.80
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med (2007) 5.39
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet (2006) 4.72
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology (2002) 4.20
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc (2004) 4.12
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07